Clinical Trial Details
| Trial ID: | L4371 |
| Source ID: | NCT04431141 |
| Associated Drug: | Teneligliptin |
| Title: | Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus |
| Interventions: | DRUG: Teneligliptin|DRUG: Empagliflozin|DRUG: Teneligliptin and Empagliflozin |
| Outcome Measures: | Primary: Cmax,ss of teneligliptin and empagliflozin, Peak Plasma Concentration (Cmax) at steady state, 72 hours|AUCτ,ss of teneligliptin and empagliflozin, Area under the plasma concentration versus time curve (AUC) at steady state, 72 hours | Secondary: Tmax,ss of teneligliptin and empagliflozin, Time to reach Cmax,ss, 72 hours|t1/2β of teneligliptin and empagliflozin, Terminal elimination half-life, 72 hours |
| Sponsor/Collaborators: | Sponsor: Handok Inc. |
| Gender: | ALL |
| Age: | ADULT |
| Phases: | PHASE1 |
| Enrollment: | 32 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2020-09-15 |
| Completion Date: | 2021-01-25 |
| Results First Posted: | |
| Last Update Posted: | 2021-11-15 |
| Locations: | Clinical Pharmacology, Asan Medical Center, Seoul, Korea, Republic of |
| URL: | https://clinicaltrials.gov/show/NCT04431141 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|